Trial Profile

A Phase Ib study evaluating MTL-CEBPA in combination with Sorafenib

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Oct 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MTL CEBPA (Primary) ; Sorafenib
Indications Liver cancer
Focus Adverse reactions

Most Recent Events

25 Oct 2018 New trial record
17 Oct 2018 According to a MiNA Therapeutics media release, this study is planned to enrol the first patient in Q4 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com